Consolidated EIP Proposal for Immunogenicity Risk Assessment Veerle Snoeck, Joanna Grudzinska Goebel on behalf of EIP
10:15
Coffee Break
In-silico and in-vitro Assays as Part of the Immunogenicity Risk Assessment
10:45
Immunogenicity potential assessment at Novartis Anette Karle, Novartis
11:15
Immunogenicity potential assessment at Pfizer Sophie Tourdot, Pfizer
11:45
Design and Implementation of a Risk-Based Strategy for Reducing Immunogenicity Risk of Protein Therapeutics Karen Heyninck, Sanofi
12:15
Lunch
13:30
Bring Your own Problems (Breakout Sessions) Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Sofie Pattijn, ImmunXperts Sophie Tourdot, Pfizer Veerle Snoeck, UCB Tim Hickling, Roche Lydia Michaut, Novartis
15:00
Coffee Break
15:30
Continue “Bring Your own Problems (Breakout Sessions)”
16:30
Closing of the Workshop Day
17:00 – 18:30
Meeting of the EIP Working Groups Members of EIP working groups
Tuesday, April 23rd 2024
09:00
Welcome and Introduction by the EIP Chairman Daniel Kramer, Sanofi
09:15
Spotlight Presentations: MHC Class I and its Importance for the Immunogenicity of Novel Modalities Morten Nielsen, Technical University of Denmark Zuben Sauna, FDA
Session 2: Prediction of Immunogenicity Chair: Sebastian Spindeldreher
10:15
EIP NCIRA Working Group Update Sophie Tourdot, on behalf of EIP
10:30
Immunogenicity: It’s Personal Annie de Groot, EpiVax
EIP Immunogenicity Assays Working Group Update Marina Ichetovkin, on behalf of EIP
14:45
Coffee Break
14:45
Poster Presentation
15:15
Domain Characterization of Bi-specifics in the ADA and in the NAb Assay Issa Jyamubandi, Resolian Bioanalytics
15:45
Case study: Developing an ADA assay with enhanced Free Drug Tolerance for Octreotide René Wuttke, Debiopharm
16:15
Phase-Appropriate Implementation of a Domain Specificity Strategy Matthias Reichel, BioAgilytix
16:45
The IVDR and its Impact on Clinical Immunogenicity Assay Development Robert Nelson, BioAgilytix
Session 3: Social Event Chair: Barbara Vercruyssen
18:00
Get Together
23:00
Good Night
Wednesday, April 24th 2024
Session 4: Immunogenicity of New Modalities Chair: Arno Kromminga
09:00
Development of an ELISpot Assay for the Assessment of AAV Peptides to Examine Immune Safety Alison Johnson, Boehringer Ingelheim
09:30
Immunogenicity Risk Assessment for mRNA/LNP Therapies Joanna Grudzinska Goebel, Bayer
10:00
Total versus Neutralizing antibody assays against Adeno-associated virus, what is the best? Vivek Nayak, UCB
10:30
Orthogonal Approach for AAV Immunogenicity Assessment: Evaluating Total and Neutralizing Antibodies Michael Tovey, SVAR
11:00
Coffee Break
11:00
Poster Presentation
Session 5: Clinical Relevance of Immunogenicity Chair: Lydia Michaut
11:30
Novel Approaches for Treatment of Autoimmunity: Application to Mitigate Immunogenicity of Biological Therapeutics? Amy Rosenberg, EpiVax
12:00
ADA Monitoring Strategy for Repetitive High Doses of Biologics Therapies: Efficiently Integrating Scientific, Technical, and Regulatory Aspects Manisha Saxena, Novartis
12:30
The Wonderful World of Immunogenicity; Scientific Understanding, Clinical Relevance, and Regulatory Necessity Floris Loeff, Sanquin
13:00
Lunch Break
Short Talks (15 minutes each)
14:15
Drug T Cell Reactivity in Delayed Type Hypersensitivity – Evaluation with Cyto-LTT Lester Thoo, ADR-AC
14:30
Evaluating Immediate Type Drug Allergy and Immunostimulation in Vitro with the Basophil Activation Test (BAT) Daniel Yerly, ADR-AC
Session 6: Regulatory Chair: Daniel Kramer
14:45
How CDER reviews Immunogenicity for Biologics- the Integrative Immunogenicity Assessment paradigm Joao A. Pedras-Vasconcelos, FDA
15:30
New approaches to assess immunogenicity risk: Regulatory considerations Daniela Verthelyi, FDA
16:00
Conference Summary & Outlook by the EIP Chairman Daniel Kramer, Sanofi
16:15
Close of the conference
NOTE: If no download icon is shown against a session the speaker has not given permission for their slides to be published.
Downloads
Posters
Celerion Low Cut Points: Where Has Our Biological Variability Gone?
KCAS Bio Monitoring immunogenicity of your candidate vaccine by ELISpot: How to reduce assay variability?
Merck Generic ADA Assay: a universal approach to enhance early phase and preclinical immunogenicity testing
Novartis In Silico Immunogenicity Profiling Based On Drug / Pathogen Analogy
EIP-PCS The EIP-Particle Characterisation Subcommittee
PEPperPRINT A Chip-based Immunogenicity Risk Assessment Tool for Therapeutic Protein Products
Sanquin Cross-reactivity of anti-drug antibodies against anti-CD20 therapeutic monoclonal antibodies with other anti-CD20 antibodies